chemotherapy (NIRVANA-Lung)

chemotherapy-UNICANCER-non-small cell lung cancer refers to the standardized chemotherapy protocols employed in the NIRVANA-Lung Phase 3 clinical trial (NCT03774732) led by UNICANCER. This trial investigates the efficacy of adding concurrent radiotherapy to a treatment regimen of pembrolizumab and chemotherapy for patients with advanced non-small cell lung cancer (NSCLC). The chemotherapy component is tailored to the patient's tumor histology: those with squamous NSCLC receive a combination of carboplatin and paclitaxel, while those with non-squamous NSCLC receive pemetrexed paired with either cisplatin or carboplatin. These cytotoxic agents are administered intravenously to disrupt DNA integrity and cellular metabolic processes, serving as a foundational systemic therapy in the management of advanced lung malignancies.

Other names

chemotherapy-UNICANCER-non-small cell lung cancerNIRVANA-Lung chemotherapy